Carcinoma Esophagus - Stage-wise Management

TNM Staging Overview (AJCC 8th Edition)

Staging Workup

• EUS (Endoscopic Ultrasound) - best for T and N staging. Sensitivity: T1 82%, T2 81%, T3 91%, T4 92%
• 18F-FDG PET-CT - detects distant metastases
• Contrast-enhanced CT chest + abdomen
• EMR for nodular T1a lesions (EUS often understages these)

Stage-wise Management

Stage 0 (Tis - High Grade Dysplasia)

• Endoscopic Eradication Therapy (EET) is the treatment of choice - preferred over esophagectomy
• Includes Endoscopic Mucosal Resection (EMR) + Radiofrequency Ablation (RFA)
• Esophagectomy is an alternative but reserved for those who fail endoscopic therapy

Stage I (T1a, N0 - Intramucosal)

• Endoscopic eradication therapy is a reasonable alternative to surgery
• M2/M3 (T1a) tumors: EMR + RFA adequate
• If nodularity present on T1a lesion by EUS - EMR is recommended as EUS often misses submucosal invasion

Stage I (T1b, N0 - Submucosal)

• Lymph node metastases found in >10% of T1b cases occultly
• Esophagectomy is generally advised
• Role of neoadjuvant chemoradiation in Stage I is unclear

Stage II-III (T2-T4a, or N+, resectable)

• Neoadjuvant chemoradiation followed by esophagectomy is the preferred approach
• The landmark CROSS trial demonstrated improved survival with carboplatin + paclitaxel + 41.4 Gy radiation before surgery
• Perioperative chemotherapy + esophagectomy (for distal adenocarcinoma) is an acceptable alternative - based on MAGIC trial (epirubicin + cisplatin + 5-FU)
• Definitive chemoradiation (without surgery) acceptable for SCC or non-surgical candidates

Esophagectomy Options

• High-volume centers have significantly lower esophagectomy mortality - patients should be referred accordingly

Post-esophagectomy Adjuvant Therapy

• Adjuvant nivolumab (anti-PD-1): CheckMate-577 trial showed significantly improved disease-free survival (22.4 months vs. 11 months) in patients with residual pathologic disease after neoadjuvant chemoradiation + esophagectomy
• Given as 240 mg every 2 weeks or 480 mg every 4 weeks for 1 year

Stage T4b / Stage IV (Unresectable / Metastatic)

• Palliative approach is the goal
• Chemotherapy regimens (same as gastric cancer, given molecular similarity via TCGA data):
  • HER2+ tumors: Trastuzumab + cisplatin/oxaliplatin + fluoropyrimidine (ToGA trial - improved OS 13.8 vs. 11.1 months)
  • HER2-negative: FOLFOX, cisplatin + 5-FU, XELOX
• Ramucirumab (anti-VEGFR2): 2nd-line, improved OS in REGARD trial (5.2 vs. 3.8 months); combined with paclitaxel in RAINBOW trial (9.6 months)
• Immunotherapy: Nivolumab + chemotherapy (CheckMate-649) and pembrolizumab approved in 1st-line metastatic disease

Special Case: Squamous Cell Carcinoma (SCC) vs Adenocarcinoma

Palliative/Symptom Management (Advanced Disease)

• Esophageal stenting - for malignant dysphagia in non-surgical candidates
• Radiation for dysphagia palliation
• Brachytherapy as an alternative to external beam

Summary Algorithm

Diagnosis confirmed (EGD + biopsy)
       ↓
Staging: EUS + PET-CT + CT
       ↓
Tis / T1a N0 → Endoscopic therapy (EMR + RFA)
T1b N0      → Esophagectomy
T2+ or N+   → Neoadjuvant CRT → Esophagectomy → Adjuvant Nivolumab (if residual disease)
             (or definitive CRT for SCC / unfit patients)
T4b / M1    → Palliative chemo ± targeted therapy ± immunotherapy ± stenting

Stage IV Carcinoma Esophagus - Detailed Management

• T4b (tumor invades aorta, vertebral body, trachea - unresectable)
• Any T, Any N, M1 (distant metastasis present)

Step 1: Mandatory Biomarker Testing (Before Any Systemic Therapy)

Step 2: Systemic Therapy - First-line

A. HER2-Positive Adenocarcinoma (~20-25% of cases)

• ToGA Trial: Trastuzumab + cisplatin + 5-FU/capecitabine
  • Median OS: 13.8 months (vs. 11.1 months with chemo alone)
• Addition of Pembrolizumab (for progression-free survival improvement) in HER2+ disease is increasingly used
• Pertuzumab (anti-HER2) can be combined with trastuzumab

B. HER2-Negative Adenocarcinoma

• Cisplatin + 5-FU (CF) - classic first-line
• FOLFOX (Folinic acid + Oxaliplatin + 5-FU) - better tolerability
• XELOX / CAPOX (Oxaliplatin + Capecitabine) - noninferior to CF, oral convenience
• Adding Docetaxel (DCF/FLOT regimen) improves outcomes but higher toxicity

• If PD-L1 CPS ≥ 10: Add nivolumab or pembrolizumab to chemotherapy (CheckMate-649, KEYNOTE-590)

C. Squamous Cell Carcinoma (SCC)

• Nivolumab + chemotherapy or Nivolumab + Ipilimumab - first-line for advanced SCC
• Pembrolizumab + chemotherapy - approved first-line (KEYNOTE-590)
• PD-L1 CPS ≥ 10: higher benefit from immunotherapy

⚠️ Overall survival on chemotherapy in metastatic disease is generally < 12 months despite treatment.

Step 3: Second-line Systemic Therapy

Step 4: Rare/Niche Targeted Therapies

Step 5: Palliation of Dysphagia (Critical in Stage IV)

1. Self-Expanding Metal Stents (SEMS) - First-line for dysphagia

• Fully covered SEMS (fc-SEMS) are the stents of choice
  • Lower tumor ingrowth vs uncovered SEMS
  • Lower migration risk vs fully plastic stents
• Provides prompt, immediate dysphagia relief
• Indicated for moderate-to-severe dysphagia not amenable to other modalities

2. Brachytherapy

• Single-dose intraluminal brachytherapy provides longer-lasting dysphagia relief than stenting
• Higher QOL scores and fewer major complications (13% vs 25% for SEMS)
• However: frequent need for rescue stents - enthusiasm has declined
• Best for: patients with mild-moderate dysphagia and longer expected survival

3. External Beam Radiation Therapy (EBRT)

• Palliative radiation for pain, dysphagia, and bleeding
• Used when stenting is not feasible or as adjunct

4. Photodynamic Therapy (PDT)

• Endoluminal obstruction management
• Less commonly used but available in specialist centres

5. Endoscopic Laser Therapy (Nd:YAG)

• Ablates intraluminal tumor tissue
• Provides temporary dysphagia relief

Step 6: Management of Malignant Tracheoesophageal Fistula (TEF)

• Suspend oral intake immediately
• Drain involved spaces (pleura/mediastinum)
• Insert fully covered SEMS (fc-SEMS) - method of choice for sealing fistula
• Fistula closure rates >70% with fc-SEMS
• "Dual stenting" (esophageal + tracheal stent simultaneously) is largely avoided due to risk of lethal vascular erosions from synergistic pressure necrosis
• Amplatzer ASD occluder has been used off-label for closure in limited studies

Step 7: Nutritional Support

• Enteral feeding via nasojejunal tube - temporary
• Percutaneous Endoscopic Gastrostomy (PEG) - if no surgical resection planned
• Jejunostomy feeding tube - standard when gastrostomy is not feasible
• IV nutritional support as needed

Step 8: Best Supportive Care (BSC)

• Pain management (WHO analgesic ladder; opioids for severe pain)
• Antiemetics, appetite stimulants
• Palliative sedation if refractory symptoms
• Hospice/end-of-life care coordination
• Multidisciplinary involvement: oncology, gastroenterology, palliative care, dietetics, psychology

Key point: BSC is always indicated in Stage IV regardless of whether active treatment is also given. It is not synonymous with "giving up" - it reduces suffering and can improve survival.

Prognosis

• The most important prognostic factors are T stage (depth of invasion) and N stage (lymph node involvement)
• Histologic type, degree of differentiation, and tumor location also affect survival

Summary Flow for Stage IV

Stage IV confirmed (M1 or T4b)
        ↓
Full molecular profiling (HER2, PD-L1, MSI, TMB, NGS panel)
        ↓
Good PS (ECOG 0-1)?
   YES → Systemic therapy:
         HER2+ → Trastuzumab + chemo (± pembrolizumab)
         HER2- → Chemo + anti-PD1 (if PD-L1+)
         SCC   → Nivolumab + chemo or nivolumab + ipilimumab
   NO  → Best supportive care alone
        ↓
Dysphagia present?
   → fc-SEMS first-line for moderate-severe
   → Brachytherapy for mild-moderate (longer survival expected)
        ↓
TEF present? → fc-SEMS + stop oral intake
        ↓
Malnutrition? → PEG / jejunostomy tube
        ↓
2nd-line on progression:
   HER2+ → Trastuzumab deruxtecan (T-DXd)
   Adeno  → Ramucirumab ± paclitaxel
   PD-L1+ → Pembrolizumab monotherapy

HER2+ Esophageal/GEJ Cancer: Can You Add Pembrolizumab Directly?

The KEYNOTE-811 Trial (Lancet, 2023) - The Key Evidence

• Pembrolizumab 200 mg IV every 3 weeks
• Combined with: trastuzumab + fluoropyrimidine (5-FU or capecitabine) + platinum (cisplatin or oxaliplatin)
• Up to 35 cycles

2023 ASCO Guideline Recommendation (Level 1 Evidence)

"For patients with HER2-positive gastric or GEJ previously untreated, unresectable or metastatic adenocarcinoma, trastuzumab plus pembrolizumab is recommended, in combination with chemotherapy."

Important Nuances You Must Know

1. PD-L1 requirement - does it matter here?

2. The triple combination, not double

• Trastuzumab alone → not enough
• Pembrolizumab alone → not enough
• Trastuzumab + Pembrolizumab without chemo → not studied in this setting

3. Chemotherapy backbone options

4. This applies to GEJ and gastric - not pure SCC

• KEYNOTE-811 enrolled adenocarcinoma of gastric/GEJ origin
• For pure esophageal SCC, HER2 is rarely overexpressed and pembrolizumab/nivolumab are used differently (with chemo, without trastuzumab)

5. Second-line after HER2+ first-line

• Trastuzumab deruxtecan (T-DXd) is the standard 2nd-line (DESTINY-GastricO2/01 trials: OS 12.5 vs 8.4 months)

Summary Regimen for HER2+ Stage IV

HER2+ (IHC 3+ or IHC 2+/FISH amplified) Esophageal/GEJ Adeno
                    ↓
   1st Line:  Pembrolizumab 200mg q3w
            + Trastuzumab 6mg/kg q3w (8mg/kg loading)
            + Platinum (cisplatin/oxaliplatin)
            + Fluoropyrimidine (5-FU/capecitabine)
            ↓ (progression)
   2nd Line:  Trastuzumab Deruxtecan (T-DXd)

Role of Immunotherapy (Nivolumab) in Stage II/III with Residual Disease - The CheckMate-577 Trial

Context: What is "Residual Disease" Here?

1. Had Stage II or III esophageal / GEJ cancer
2. Received neoadjuvant chemoradiation (e.g. CROSS regimen: carboplatin + paclitaxel + 41.4 Gy)
3. Underwent R0 esophagectomy (complete resection, clear margins)
4. But on final pathology - still had residual viable tumor in the specimen

The CheckMate-577 Trial - Key Evidence

Results

The DFS benefit was doubled - from 11 months to 22.4 months. This was consistent across both SCC and adenocarcinoma histologies.

Why Nivolumab and NOT Pembrolizumab Here?

Who Exactly Qualifies - Strict Criteria

Key point: If the patient achieved a complete pathological response (ypT0N0M0), they do NOT receive adjuvant nivolumab. This drug is specifically for those with remaining disease.

What About Patients Who Had Perioperative Chemo (Not CRT)?

• CheckMate-577 specifically enrolled patients after chemoRADIATION followed by surgery
• Patients who received perioperative chemotherapy alone (FLOT/MAGIC regimen) and have residual disease are not covered by this trial's indication
• For those patients, the adjuvant role of immunotherapy is being explored in trials like VESTIGE (EORTC 1707) - which randomized HER2- gastric/GEJ patients with ypN+ or R1 after perioperative chemo to adjuvant nivolumab + ipilimumab vs. chemo (PMID: 39542422, Ann Oncol 2025)

Ongoing Trials Exploring Neoadjuvant Immunotherapy (Future Landscape)

Current Standard of Care Summary for Stage II/III

Stage II/III esophageal / GEJ cancer
          ↓
Neoadjuvant CRT (CROSS: Carboplatin + Paclitaxel + 41.4 Gy)
          ↓
R0 Esophagectomy
          ↓
  Pathology result?
     ↙                ↘
ypT0N0M0            Residual disease present
(pCR achieved)        (ypT+ or ypN+)
     ↓                     ↓
Surveillance         ADJUVANT NIVOLUMAB
only                 240mg q2w OR 480mg q4w
                     × 1 year (16 cycles)
                     → Median DFS: 22.4 months
                       (vs 11 months without)

FDA Approval Status

Completely resected esophageal or GEJ cancer with residual pathologic disease who received neoadjuvant chemoradiation - based on CheckMate-577.